Delcath Systems (NASDAQ:DCTH) Delivers Shareholders Incredible 358% Return Over 1 Year, Surging 20% in the Last Week Alone
CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21
Delcath Systems Announces FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Combination With Standard Of Care In Liver-Dominant Metastatic Colorectal Cancer
Express News | Delcath Systems Inc - Primary Endpoint Data Expected by End of 2027
Express News | Delcath Systems Announces FDA Clearance of Ind Application for Phase 2 Clinical Trial of Hepzato™ in Liver-Dominant Metastatic Colorectal Cancer
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $22